Collection 16 November 2020

Recent advances in malaria vaccines

Despite a marked decrease in cases and mortality, malaria is still estimated to result in over 405,000 deaths annually. Although a first vaccine against P. falciparum malaria is being piloted, much work is still needed to achieve the Global Technical Strategy for Malaria 2016–2030 of the World Health Assembly to reduce global malaria incidence and mortality rates by at least 90% by 2030. The latest advances in malaria vaccine research are compiled in this collection.

Research Highlights

Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria
- David C. Kaslow
EditorialOpen Access20 Nov 2020 npj Vaccines
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
- Antje Blank
- Kristin Fürle
- Hermann Bujard
ArticleOpen Access31 Jan 2020 npj Vaccines
Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
- Wei-Chiao Huang
- Bingbing Deng
- Jonathan F. Lovell
ArticleOpen Access18 Mar 2020 npj Vaccines
Malaria vaccines since 2000: progress, priorities, products
- Patrick E. Duffy
- J. Patrick Gorres
Review ArticleOpen Access9 Jun 2020 npj Vaccines
AgBR1 antibodies delay lethal Aedes aegypti-borne West Nile virus infection in mice
- Ryuta Uraki
- Andrew K. Hastings
- Erol Fikrig
Brief CommunicationOpen Access8 Jul 2019 npj Vaccines
Recombinant measles vaccine expressing malaria antigens induces long-term memory and protection in mice
- Marie Mura
- Claude Ruffié
- Frédéric Tangy
ArticleOpen Access27 Feb 2019 npj Vaccines
Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development
- Arnaud Chêne
- Stéphane Gangnard
- Benoît Gamain
ArticleOpen Access17 Jul 2018 npj Vaccines
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
- Tommy Rampling
- Katie J. Ewer
- Adrian V. S Hill
ArticleOpen Access9 Oct 2018 npj Vaccines
A Plasmodium berghei sporozoite-based vaccination platform against human malaria
- António M. Mendes
- Marta Machado
- Miguel Prudêncio
ArticleOpen Access24 Aug 2018 npj Vaccines
Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells
- Jing Jin
- Richard D. Tarrant
- Simon J. Draper
ArticleOpen Access17 Aug 2018 npj Vaccines
Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial
- Kavita Singh
- Paushali Mukherjee
- Chetan E. Chitnis
ArticleOpen Access28 Sep 2018 npj Vaccines
Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission
- Gaspar E. Canepa
- Alvaro Molina-Cruz
- Carolina Barillas-Mury
ArticleOpen Access10 Jul 2018 npj Vaccines
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody

The structure of a neutralizing human monoclonal antibody isolated from an individual immunized in a Plasmodium vivax Duffy binding protein vaccine clinical trial, in complex with its target, elucidates the mechanism by which parasite invasion of immature red blood cells is inhibited.
- Thomas. A. Rawlinson
- Natalie M. Barber
- Simon J. Draper
Article27 May 2019 Nature Microbiology
Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP

The structures of two neutralizing human monoclonal antibodies against Plasmodium vivax Duffy-binding protein (DBP) isolated from an individual with naturally acquired immunity, bound to DBP, reveal how such antibodies prevent parasite entry into reticulocytes.
- Darya Urusova
- Lenore Carias
- Niraj H. Tolia
Article27 May 2019 Nature Microbiology
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs

Characterization of 200 antibodies that bind a malaria parasite protein provides insights that could enable better vaccine design.
- Rajagopal Murugan
- Stephen W. Scally
- Hedda Wardemann
Article25 May 2020 Nature Medicine
Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity

Duffy binding protein (DBP) of Plasmodium vivax is important for invasion and is a potential vaccine candidate. Here, the authors show that PvDBP gene amplification protects P vivax in vitro against invasion inhibitory human monoclonal antibodies and is associated to infection of patients with PvDBP binding inhibitory antibodies.
- Jean Popovici
- Camille Roesch
- Benoit Witkowski
ArticleOpen Access19 Feb 2020 Nature Communications
Targets of complement-fixing antibodies in protective immunity against malaria in children

Antibodies against Plasmodium falciparum merozoites that fix complement can inhibit blood-stage replication. Here, Reiling et al. show that complement-fixing antibodies strongly correlate with protective immunity in children, identify the merozoite targets, and predict antigen combinations that should result in strong protection.
- Linda Reiling
- Michelle J. Boyle
- James G. Beeson
ArticleOpen Access5 Feb 2019 Nature Communications
Outcomes of controlled human malaria infection after BCG vaccination

Immune activation induces long-term alterations of setpoints, impacting responses to subsequent unrelated stimuli. Here the authors show that volunteers vaccinated with BCG respond to controlled human malaria infection with increased clinical symptoms and an inverse correlation between immune activation markers and parasitemia.
- Jona Walk
- L. Charlotte J. de Bree
- Robert W. Sauerwein
ArticleOpen Access20 Feb 2019 Nature Communications
A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates

Proof of protection against blood-stage P. falciparum malaria by a single immunological mechanism has been elusive. Here, using engineered anti-PfRH5 chimeric monoclonal antibodies in non-human primates, the authors show that high levels of merozoite-neutralizing antibodies can achieve protection.
- Alexander D. Douglas
- G. Christian Baldeviano
- Simon J. Draper
ArticleOpen Access26 Apr 2019 Nature Communications
Vaccine candidates for poor nations are going to waste

Promising immunizations for diseases that affect mostly people in low- and middle-income countries need help getting to market, urge David C. Kaslow and colleagues.
- David C. Kaslow
- Steve Black
- Rino Rappuoli
Comment18 Dec 2018 Nature
Maternal antibodies block malaria
- Michal Fried
- François Nosten
- Patrick E. Duffy
Scientific Correspondence29 Oct 1998 Nature
Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites
- Anthony A. Holder
- Michael J. Lockyer
- Robert R. Freeman
Letter19 Sep 1985 Nature

Recent advances in malaria vaccines

Research Highlights

Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria

Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment

Malaria vaccines since 2000: progress, priorities, products

AgBR1 antibodies delay lethal Aedes aegypti-borne West Nile virus infection in mice

Recombinant measles vaccine expressing malaria antigens induces long-term memory and protection in mice

Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

A Plasmodium berghei sporozoite-based vaccination platform against human malaria

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial

Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission

Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody

Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP

Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs

Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity

Targets of complement-fixing antibodies in protective immunity against malaria in children

Outcomes of controlled human malaria infection after BCG vaccination

A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates

Vaccine candidates for poor nations are going to waste

Maternal antibodies block malaria

Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites

Search

Quick links